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Abstract 
Background: The aim of this study was to compare the safety and intra-individual contrast enhancement of low-
osmolar monomeric iohexol and the iso-osmolar dimeric iodixanol in body computed tomography (CT) scanning.
Methods: In this single center, double-blind, prospective study, a total of 2000 consecutive patients undergoing 
adult body CT scanning were prospectively enrolled, with 1000 patients assigned to iodixanol and 1000 patients 
assigned to iohexol. In both groups, the contrast medium was injected at the rate of 3.5 ml/s. Subjective assessment 
of image quality for each image was determined using a 3-grading scale by three reviewers. Patients were monitored 
with questioning and vital signs before injection, immediately after injection, and at 24 and 48 h. Extensive laboratory 
evaluation also was performed.
Results: Laboratory results showed no significant difference across groups. There were also no detectable differences 
in image quality between the two contrast groups in this study. The total adverse reactions occurred in less than 1 % 
of individuals receiving iodixanol comparing to 2.5 % in iohexol group (P < 0.05). Among them, only 0.7 % patients 
injecting iodixanol suffered immediate events, comparing to 2 % patients in iohexol group. In all, 0.2 % patients with 
iodixanol and 0.5 % with iohexol had late allergic reaction. Further, No deaths occurred in any of the two groups.
Conclusions: The iso-osmolar iodixanol provides image quality compared with that of iohexol, with lower incidence 
of adverse events.
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Background
The intravenous injection of contrast materials for medi-
cal imaging is usually a safe procedure and has been 
widely used throughout the world, over the last few dec-
ades (Casserbaum 1965). However, some individuals 
may undergo discomfort, experience allergy-like reac-
tions or even adverse events (Becher et  al. 2005). The 
hyper-osmolality is believed to be an important factor for 
systemic adverse reactions of contrast agents and respon-
sible for local symptom from contrast media extravasa-
tions (Lee et al. 1996). More efficacious and safe contrast 
agents have been extensive developed to benefit the 
patients’ care in terms of their decreasing osmolality.
Iodixanol (Hengrui, Jiangsu, China) is a water-soluble, 
nonionic, dimeric, isosmolar radiographic material for 
intravascular injection (Spencer and Goa 1996). Preclini-
cal researched have detected better toxicological phar-
macological and physicochemical properties of iodixanol 
(Wilcox et  al. 1987). A latter double blind, randomized, 
prospective, multi-center study has concluded that 
iohexol was more nephrotoxic among high risk groups, 
compared with the iso-osmolar, agent iodixanol (Doerfler 
et  al. 1999). Numerous clinical trials also demonstrated 
comparable safety and efficacy in body computed tomog-
raphy usage (Lee et  al. 1996). Iohexol is another exten-
sively used low-osmolar monomer non-ionic contrast 
medium, which is considered to safe, efficient and be 
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well-tolerated for the head and body computed tomogra-
phy (Almen 1983).
Therefore, we try to perform an intra-individual 
evaluation of the degrees of image quality and safety 
enhancement achieved by iohexol and iodixanol in body 
computed tomography (CT) scanning under the stand-




This was a randomized study conducted from April 
2014 to 2015 at Chongqing City Chinese Medicine Hos-
pital. The consecutive patients, who were scheduled 
to undergo a follow-up contrast-enhanced CT for the 
assessment of pain or the evaluation of suspected masses 
in organs, were prospectively enrolled in this study. In 
brief, nine variables were assigned as exclusion crite-
ria: (1) a known history of hypersensitivity to iodine, (2) 
pregnancy, (3) lactation, (4) clinically unstable condition, 
(5) having received contrast media  <7  days before the 
procedure, (6) cardiogenic shock, (7) known renal dys-
function, (8) pulmonary edema, (9) mechanical ventilator 
support. The subjects were randomized into two groups 
by the permuted block randomization method. Subjects 
allocated to the experimental arm underwent body com-
puted tomography scanning using the contrast medium 
of iodixanol, whereas iohexol was used in the controlled 
arm of the trial.
Methods
The radiology nurse established the heparin lock intra-
venous line before injection. Both of the contrast mate-
rial were pre-warmed to 37  °C prior for intravascular 
use. The regional difference in contrast agent wash-in 
and wash-out time constants were identified as the main 
mechanism of delayed contrast enhancement on scan 
images. The highest attenuation difference for idoix-
anol on delayed contrast-enhanced images was achieved 
4 min post injection comparing to 3 min for iohexol. In 
this trial, 1000 individuals were injected 100  ml iohexol 
300 mg I/ml, while the other 1000 participants received 
intravenously 100 ml iodixanol 300 mg I/ml. The whole 
participants were monitored through completion of 
injections and throughout the scanning. In addition, 
these patients were further interviewed at the end of 
the test immediately, at 1 h, as well as at 24 h, concern-
ing any local or systemic syndrome. The radiology nurse 
recorded vital signs at the time of interview. Urine and 
blood specimens were also obtained at the aforemen-
tioned time. The CTDIvol was 13.82 mGy for the 80 kV 
scan protocol.
Laboratory analysis
This analysis was performed on both venous blood sam-
ples and voided urine samples, which were collected in 
a blinded fashion and measured by auto-analyzer of the 
clinical laboratory in Chongqing City Chinese Medicine 
Hospital. Generally, blood samples included tests for 
potassium chloride, platelet count, alanine aminotrans-
ferase, white blood cells, eosinophils, lymphocytes, 
aspartate aminotransferase, hemoglobin, red blood cells, 
sodium, blood urea nitrogen, creatinine, basophils, hem-
atocrit, lactate dehydrogenase, and neutrophils. Urine 
samples usually contain occult blood (red blood cells), 
glucose, pH, specific gravity, and protein.
Assessment of contrast enhancement on images
All participants were instructed to practice breath hold-
ing before scanning which was all performed on a sec-
ond-generation 64-slice scanner. Three experienced CT 
radiologists, each with more than 5  years’ work experi-
ence was allocated in a group, to evaluate the images 
independently. Contrast quality grades should arrive at 
consensus for each diagnostic item by discussion. None 
radiologists had been involved in the patients recruit-
ing. The radiologists were fully unaware of the original 
examination interpretation results and the specific con-
trast material injected. Contrast quality grades which is 
referenced as diagnostic images quality in this passage, 
which could be classified into three distinct grades as fol-
lows: Grade one is optimal, the one that provides optimal 
information to make a definitive decision. Grade two is 
the suboptimal choice, which provides less definitive 
information to make a suboptimal decision, which was 
also taken, if the images enhancement could not arrive 
at the optimal conditions in any aspect. Grade three is 
definitely not determinative, could not offer sufficient 
information to make the diagnosis. Results of this trial 
would be presented for all participants recruited in this 
research.
Contrast agent reactions
Based on the reaction severity according to the criteria, 
patients’ reactions to the contrast enhanced CT could 
be graded as mild, moderate, or severe (Pintassilgo San-
tos et  al. 2009). Discomfort related to the injection was 
classified into three grades as follows: mild, moderate, 
or severe, with the definition of subjective feeling, which 
resulted from physiology and psychology. Mild contrast 
reactions including rash, emesis, peculiar taste, itching, 
did not require any treatment. Moderate events were 
of any aforementioned in more advanced degree and 
required close monitoring and immediate therapy. Seri-
ous reactions were regarded as life-threatening events 
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and more robust solutions were further required. All 
incidents accompanied with the material injection were 
recorded in this institution. For each adverse event, both 
supervising CT radiologists and technologists involved, 
completed the incidents reports, which contain the per-
sonal characteristics, contrast medium as well as date of 
the scanning and the events descriptions. These reactions 
could be classified into either immediate or delayed event 
according to the events onset time. Immediate events 
were those that occur within 1  h and were reported by 
experimentalists nearby or patients. Delayed reactions 
were subsequent clinical symptoms up to 7  days from 
time of intravenous use. The patients or their compan-
ions reported these information to us voluntarily.
Statistical analysis
Quantitative variables were summarized by use of 
descriptive statistics, expressed as mean  ±  SD, while 
categorical variables were expressed as frequencies or 
percentages. Personal characteristics were compared 
between two contrast media by Student’s t test. Fisher’s 
exact test was used to evaluate the frequency of adverse 
events and discomfort. P values  <0.05 were considered 
statistically significant difference. Statistical analysis was 
performed by spss version 18.0 for Mac.
Ethics statement
This study was approved by local institutional review 
boards, and written informed consents were obtained 
from all patients before they were randomly assigned.
Results
Patients’ characteristics
2702 participants were assessed for eligibility between 
April 2014 and 2015. Among these, 318 individuals met 
at least one of the specified exclusion criteria in this 
study, while 388 patients declined to participate the 
research. The other participants (n  =  2004) were ran-
domly assigned either to an iohexol or iodixanol program 
(Fig.  1). One were excluded, among these enrolled par-
ticipants, on account of a serious hypersensitivity event 
in iohexol group and three were excluded because rand-
omization assignment was not match the preferred con-
trast medium (one in iohexol and two in iodixanol group) 
of their own. No significant difference was detected 
between two groups for the demographic characteristics, 
as shown in Table 1.
Image enhancement and quality
With regard to the overall enhancement, the diagnostic 
images were performed in CT room, which deployed 
the same monitors and similar machines. These images 
were diagnosed and classified by onsite-experienced 
investigators into three grades. As Table  2 shown, 
only 11 participate were regarded as Grade 3 in iodix-
anol group while 21 patients were considered as 
Grade 3 in iohexol group. On the contrary, the diag-
nostic images in iodixanol group was evaluated as 
Grade 1 for 80.9  %  (809/1000) of the individuals and 
82.6 % (826/1000) of the patients in the iohexol group. In 
Grade 2163 images were considered suboptimal in iodix-
anol group and 170 in iohexol. No significant difference 
was detected in image quality between contrast medium 
among the grades (P > 0.05, Table 1).
Comparison of the time duration with vascular attenu-
ation values equal to or above 300  HU revealed no sta-
tistically significantly difference between iohexol and 
iodixanol for aorta (350 vs 293; P = 0.03, Table 3).
Laboratory results
In brief, we did not detect any significant difference 
between the two groups in all laboratory results meas-
ured. Neither clinically significant changes nor any rel-
evant trends, which demonstrated toxicity attributable to 
any contrast agents, were founded in these specific labo-
ratory results (data not shown). However, among these 
patients, thirty patients in iohexol group had deviated 
from the maximum limits of normal reference range, and 
turned into normal in 3 days post-injection. The increase 
in serum creatinine was considered to be clinically rele-
vant by radiologists. Ten patients in iodixanol group had 
increase in serum creatinine and decreased to normal 
reference range in 3  days post-injection. However, one 
participant receiving iodixanol got 1.3  mg/dl in creati-
nine level on the day prior to the research, and 1.8 mg/dl 
after 4 days. He received low dose gentamycin, and ampi-
cillin therapy with the decrease of creatinine 2 days later. 
Summary results for creatinine are presented in Table 4.
Safety results
The overall incidence of adverse reaction was low for 
iodixanol (0.9 %). A nearly threefold increase in the over-
all adverse events frequency was detected with iohexol 
(2.5  %), which was significant (P  <  0.05, Fisher’s exact 
test). Both of the immediate adverse events and delayed 
ones experienced increased in iohexol groups compared 
with iodixanol, while the changes were not significant 
(P  >  0.05). Though immediate adverse reactions pre-
dominated in both contrast materials, the rate of delayed 
adverse reactions was much greater with iohexol group 
(P > 0.05). For both mediums, most of the adverse reac-
tions were of mild severity (87 % iohexol vs 89 % iodix-
anol). For moderate events combined, the percentage of 
iodixanol was higher than iohexol (2.4 % iohexol vs 1 % 
iodixanol). Futher, only one patients suffered severe side 
effects after injecting iohexol. For both agents, neither a 
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monthly nor a seasonal trend in the incidence of adverse 
reactions during the study period was included in the 
study. The results of this study are summarized in Table 5.
The profile of adverse reactions is similar in two 
groups. Almost all adverse reactions had a cutaneous 
component (75  % in iohexol vs 90  % in iodixanol, data 
not shown), with most commonly urticaria. However, 
respiratory and gastrointestinal was the next most fre-
quent symptom, and the frequency of them was higher 
in iohexol group. In addition, two severe reaction was 
observed with iohexol while none was found with 
iodixanol. In this particular event, both of the patients 
developed erythemas immediately, have profound hypo-
tension, loss of consciousness at the injection of iohexol. 
Luckily, they responded to administration of oxygen, 
Fig. 1 Flow of patients through the study
Table 1 Patient demographic information
Safety parameter Iodixol Iohexol P value
n = 1000 n = 1000
Male, n (%) 549 (54.9) 631 (63.1) 0.782
Age (years) 52 ± 13.3 55 ± 13.6 0.652
BMI (kg/m2) 25.2 ± 3.1 24.9 ± 2.8 0.263
Baseline SCr (mg/dl) 1.46 ± 1.2 1.53 ± 0.72 0.397
Baseline CrCl (ml/min) 47.51 ± 4.3 49.21 ± 5.7 0.421
Table 2 Diagnostic image quality
Iodixanol Iohexol P value
n = 1000 n = 1000
Grade 1 826 (82.6 %) 809 (80.9 %)
Grade 2 163 (16.3 %) 170 (17 %) 0.178
Grade 3 11 (1.1 %) 21 (2.1 %)
Table 3 CT HU for aorta
Iodixanol Iohexol P value
HU 350 ± 25.7 293 ± 18.6 0.032
Table 4 Summary values for patient creatinine levels
Serum creatinine (mg/dl) Iodixanol group Iohexol group P value
Baseline level 1.46 ± 1.23 1.53 ± 0.72 0.397
At day 2 1.43 ± 1.52 1.56 ± 0.68 0.432
At day 3 1.43 ± 1.61 1.58 ± 0.59 0.451
>10 % rise in creatinine 14 27 0.028
>25 % rise in creatinine 1 1 1
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fluid resuscitation, and epinephrine. After transferring 
to the emergency department, the patients made a com-
plete recovery. No deaths or other severe events occurred 
in this study. Pulse rate as well as systolic and diastolic 
blood pressure showed transient, mild variation within 
normal ranges for almost all individuals in all recordings. 
Mean values of all procedures stayed ordinarily within a 
single standard deviation of means. The five patients who 
showed greater ranges were diagnosed to be clinically 
non-relevant by two cardiologists. No significant of vital 
signs and the relation between types of contrast material 
injected could be detected.
In the follow-up research, one patient had severe skin 
rash 2  days after injecting iohexol. The skin lesion had 
pruritus, edema, erythema, urticaria, and exanthema. 
Receiving low dose (0.5  mg/kg) oral prednisolone ther-
apy result in the resolution of skin lesion 1 week later. 
All researches were successfully completed in all of the 
enrolled individuals.
Discussion
The data of this research detected similar diagnos-
tic quality enhancement by iohexol and iodixanol. The 
comparison was performed by paralleled total iodine 
amounts and identical iodine delivery rates under stand-
ardized conditions in intra-individuals. The overall 
diagnostic quality was evaluated as optimal in 80.9  % 
(809/1000) of the individuals receiving iodixanol and 
82.6 % (826/1000) of the groups injecting iohexol. We did 
not detect any significant difference in diagnostic image 
enhancement among the three grades between contrast 
medium (P < 0.05). In addition, The impact of iodixanol 
also persisted longer than the other agent. The result 
is similar to the detection of Elmstahl et  al. (2007). The 
detection might also indicate that the increased quality 
enhancement observed with iodixanol injection might 
provide improved images diagnosis and detailed descrip-
tions of several organic disease. More importantly, 
the iso-osmotic agent might be more efficient and the 
smaller doses of iodixanol could pose similar diagnostic 
enhancement compared with larger doses of the other 
one when imaging some specific organ.
There are distinct types of complications following 
intravenous use: soft tissue injury, direct chemical tox-
icity, nephrotoxicity, and anaphylactic reactions (Leow 
et  al. 2015; Li et  al. 2015; McAlister and Kissane 1990). 
Nearly 2 % of the patients in this study experience adverse 
reactions related with intravenous contrast medium, 
similar to the dictation of Ho et al (Ho et al. 2007). Late 
reactions are reported with frequencies nearly 20 %. Our 
observation indicates that compared to iohexol, iodix-
anol is associated with a lower frequency of late reac-
tion (P < 0.05). These results suggested that there exists 
the increased frequency of late reaction with hypotonic 
contrast medium compared to hyperosmotic contrast 
medium. This finding is also consistent with the litera-
ture that suggests that delayed reactions are more com-
mon with nonionic dimers than with monomers (Webb 
et  al. 2003). Definitely, the physiological background of 
delayed reaction is largely unknown. In this study, the 
incidence of allergic reaction was 2  % among all patici-
pants, slightly less than previous study (Li et al. 2015). In 
all, 0.2 % patients with iodixanol and 0.5 % with iohexol 
had late allergic reaction. These results is similar to the 
report that the adverse reaction was minimal for patients 
receiving iodixanol compared with individuals injecting 
iohexol (Chalmers and Jackson 1999). During this study, 
no significant differences were account for the different 
frequency of adverse reactions in the methods of report-
ing adverse events with either contrast medium.
Contrast nephropathy (CN) is the complex complica-
tions of arteriography action, which could be defined as 
the acute renal function impairment, caused by contrast 
material injection (McCullough et  al. 1997; Lindholt 
2003). The clinical presentation of CN is distinct, having a 
temporal relation with the high-risk patients groups and 
the onset of a serum creatinine levels increase within the 
24 h to 5 days following the injection. CN could be diag-
nosed if the value of serum creatinine is rising by 0.5 mg/
dl or greater than 25 % of baseline or more. A previous 
study has demonstrated that iohexol was slightly more 
nephrotoxic compared with iodixanol (Chalmers and 
Jackson 1999). Accordingly, in this research, 10 % patients 
receiving iodixanol had an increase in serum creatinine 
greater than 10 % of baseline in the week following scan-
ning, compared with 15 % in the iohexol group (P > 0.05). 
Several previous studies have demonstrated that con-
trast medium could pose direct cytotoxic effects on renal 
structures, such as glomerulus, kidney tubules. Until 
now, several hypothesis have been proposed to explore 
the further mechanisms, including the discovery of dis-
turbed renal perfusion/hypoxia, the renal tubular epi-
thelium caused by direct toxicity of contrast medium, or 
Table 5 Patients safety results
Safety parameter Iodixanol Iohexol P value
Total
 Adverse events 9 25 0.04
 Immediate events 7 20 0.018
 Delayed events 2 5 0.452
Severity
 Mild 8 22 NA
 Moderate 1 2 NA
 Severe 0 1 NA
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apoptosis of glomerular, and altered glomerular function 
(Gyoten 1998; Hizoh and Haller 2002; Duarte et al. 1999; 
Tervahartiala et al. 1993). However, there is no evidence 
that the use of any medicine could provide any significant 
prophylactic benefit, based on these mechanisms. The 
serious complications in the high-risk patients’ groups, 
including anaphylactic shock, acute renal failure, still 
should be managed by hemodialysis. Thus, further meas-
ures and researches about cytokines and complement 
profiles are needed in sequential studies.
A limitation of our research, consistent with previ-
ous contrast material clinical trials, is the comparatively 
small patients population with special species of chronic 
disease, such as diabetes and hypertension without 
CKD. The previous studies has indicated that non-dia-
betic patients with preexisting renal insufficiency and 
patients with diabetes mellitus are conditions clinically 
carrying a high risk of nephrotoxicity events resulted 
by contrast material (Gavant and Siegle 1992). In this 
research, the data of body CT scanning revealed that 
iodixanol is superior to iohexol in safe and efficacy in the 
concentrations tested with 15 diabetes mellitus and 10 
renal insufficiencies. In the iodixanol group, none dia-
betic patient with renal insufficiency had CN while five 
diabetes mellitus with normal renal function experience 
CN in the iohexol group. However, there were no signifi-
cant difference in serum creatinine levels, and no death 
adverse reactions occurred in these overall samples. Our 
experience is mirrored by that of others who have used 
iodixanol for excretory urography (Gavant and Siegle 
1992). Although these special patient populations were 
small, and the broad safety conclusions of these two con-
trast agents are beyond the scope or intent of this study, 
we do suppose that further researches are needed to add 
to the validity of this study in terms of applicability to 
clinical practice.
Above all, there were no apparent differences in the 
diagnostic images enhancement. The incidence of adverse 
reactions with the universal use of iodixanol for CT were 
lower compared with iohexol and within the range of 
previously reported incidences for other contrast mate-
rial. In addition, in our experience, the rate of immediate 
and delayed adverse reactions were significantly greater 
with iohexol than iodixanol. No seasonal influence was 
detected to affect the incidence of adverse events com-
pared with either contrast material. Additional studies 
will be needed to further illuminate the iodixanol clinical 
properties.
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